GlassScriptPhysician profile
Leah Aminov
NPI 1700407152
$5,342.30
in general payments reported to CMS, 2019-2025
27 companies · $3,029 in 2025
The $3,029 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.00 · 2022: $705 · 2023: $621 · 2024: $972 · 2025: $3,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $977.18 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $809.78 | 2024-2025 | Zoryve |
| Abbvie INC. | $578.49 | 2023-2025 | |
| Revance Therapeutics, INC. | $474.57 | 2025 | Daxxify |
| Pfizer INC. | $449.65 | 2022-2025 | |
| Amgen INC. | $383.37 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $237.67 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $224.16 | 2023-2025 | Tremfya |
| Genzyme Corporation | $212.72 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $198.79 | 2023-2025 | Ilumya |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Botanix Sb INC | $89.58 | 2025 | Sofdra |
| Organon LLC | $89.06 | 2025 | Vtama |
| Lilly USA, LLC | $75.11 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Verrica Pharmaceuticals INC. | $74.82 | 2024-2025 | Ycanth |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $69.83 | 2025 | Bimzelx |
| Almirall LLC | $64.46 | 2022-2023 | Klisyri |
| Dermavant Sciences, INC. | $38.84 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $35.08 | 2025 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.39 | 2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $24.98 | 2024 | |
| Biofrontera INC. | $21.23 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Mannkind Corporation | $20.99 | 2022 | |
| Lnhc, INC | $19.28 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.73 | 2025 | Cabtreo |
| Eisai INC. | $17.47 | 2022 | |
| Journey Medical Corporation | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Aminov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.